Rasagiline and Umeclidinium and vilanterol interaction
Rasagiline and Umeclidinium and vilanterol: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Rasagiline label · effective 2020-06-30
Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications.
Severe hypertension has been reported in patients taking the recommended dose of rasagiline and ophthalmic drops containing sympathomimetic medications.
Nevertheless, caution should be exercised when concomitantly using recommended doses of rasagiline with any sympathomimetic medications including nasal, oral, and ophthalmic decongestants and cold remedies.
Sympathomimetic Medications The concomitant use of rasagiline and sympathomimetic medications was not allowed in clinical studies.
Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors.
From the Umeclidinium and vilanterol (Umeclidinium and Vilanterol Ellipta) label · effective 2024-11-22
• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution.
Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, and QTc Prolonging Drugs Vilanterol, like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the…
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.